In patients with evaluable response and measurable lesion size, 20 of 24 samples (83.3%) of tumor cells did not express PD-L1, but 23 of 24 samples (95.8%) of the TME immune cells had PD-L1 expression ≥1% (Figure 2). Here, CD274 is linked to neoplasm.